Nutritional Support for Cardiac Rehabilitation

Sponsor
Fondazione Don Carlo Gnocchi Onlus (Other)
Overall Status
Completed
CT.gov ID
NCT04738994
Collaborator
Azienda Ospedaliero-Universitaria Careggi (Other), University of Florence (Other)
27
1
2
19.2
1.4

Study Details

Study Description

Brief Summary

In this randomized trial the primary outcome is to assess if high doses of whey protein supplement may lower pro-inflammatory interleukin 6 (IL-6).

Hypothesis: Secondary outcomes are to assess if high doses of whey protein supplement may lower pro-inflammatory interleukin 1β (IL-1 β), tumor necrosis factor and C Reactive Protein (CRP); may increase anti-inflammatory interleukin 10 (IL-10) plasma concentrations and may change Gut Microbiota (GM) composition.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: whey protein-enriched nutritional supplement
  • Other: Control group
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
27 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Whey Protein-enriched Nutritional Supplement on Gut Microbiota and Inflammatory Status, in Patients Attending a Cardiac Rehabilitation Program
Actual Study Start Date :
May 25, 2018
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: whey protein-enriched nutritional supplement

Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water

Dietary Supplement: whey protein-enriched nutritional supplement
Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water

Active Comparator: Control group

Standard hospital diet

Other: Control group
Standard hospital diet

Outcome Measures

Primary Outcome Measures

  1. Pro-inflammatory cytokine interleukin 6 (IL-6) [Baseline (T0) and day 15 (T1)]

    Change in IL-6 [Time Frame: after 15 days (T1) from baseline (T0)]

Secondary Outcome Measures

  1. Pro-inflammatory cytokine interleukin 1beta (IL-1β) [Baseline (T0) and day 15 (T1)]

    Change in IL-1β [Time Frame: after 15 days (T1) from baseline (T0)]

  2. Tumor Necrosis Factor (TNF) [Baseline (T0) and day 15 (T1)]

    Change in TNF [Time Frame: after 15 days (T1) from baseline (T0)]

  3. C-Reactive Protein (CRP) [Baseline (T0) and day 15 (T1)]

    Change in CRP [Time Frame: after 15 days (T1) from baseline (T0)]

  4. Anti- inflammatory cytokine interleukin 10 (IL-10) [Baseline (T0) and day 15 (T1)]

    Change in IL-10 [Time Frame: after 15 days (T1) from baseline (T0)]

  5. Gut Microbiota (GM) [Baseline (T0) and day 15 (T1)]

    Change in GM [Time Frame: after 15 days (T1) from baseline (T0)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admission for cardiac rehabilitation

  • Signed informed consent

Exclusion Criteria:
  • Patient unable to eat orally

  • Eating disorders

  • Indication to Levodopa therapy

  • Gastrointestinal malignant diseases

  • Known kidney failure

  • Known liver failure

  • Previous antibiotic therapy

  • Refusal

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione Don Carlo Gnocchi Firenze Italy 50143

Sponsors and Collaborators

  • Fondazione Don Carlo Gnocchi Onlus
  • Azienda Ospedaliero-Universitaria Careggi
  • University of Florence

Investigators

  • Principal Investigator: Chiara F Gheri, MD, Fondazione Don Carlo Gnocchi Onlus

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fondazione Don Carlo Gnocchi Onlus
ClinicalTrials.gov Identifier:
NCT04738994
Other Study ID Numbers:
  • wheyprotein1_FDG
First Posted:
Feb 4, 2021
Last Update Posted:
Feb 4, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondazione Don Carlo Gnocchi Onlus

Study Results

No Results Posted as of Feb 4, 2021